T3 Pharmaceuticals AG
🇨ðŸ‡Switzerland
- Country
- 🇨ðŸ‡Switzerland
- Ownership
- Subsidiary
- Established
- 2015-01-01
- Employees
- 1
- Market Cap
- -
- Website
- http://www.t3pharma.com
Clinical Trials
2
Active:0
Completed:0
Trial Phases
1 Phases
Phase 1:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
Phase 1
2 (100.0%)First in Human Study of T3P-Y058-739 (T3P)
Phase 1
Recruiting
- Conditions
- Advanced Solid Tumor
- Interventions
- Drug: Pembrolizumab+T3P-Y058-739Drug: T3P-Y058-739 (IV)Drug: T3P-Y058-739 (IT)
- First Posted Date
- 2021-11-15
- Last Posted Date
- 2025-04-25
- Lead Sponsor
- T3 Pharmaceuticals AG
- Target Recruit Count
- 100
- Registration Number
- NCT05120596
- Locations
- 🇪🇸
Vall d'Hebron Institute of Oncology, Barcelona, Spain
🇬🇧University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom
🇪🇸Institut Catala D'oncologia, L'Hospitalet De Llobregat, Spain
News
No news found